Cargando…

Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature

BACKGROUND: Zoledronic acid is an intravenous, highly potent aminobisphosphonate for use in patients with primary or secondary osteoporosis. Zoledronic acid-induced prolonged side-effects are well known and quite common. However, severe side-effects can be a threat to life. We report a case of sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nurmi-Lüthje, Ilona, Lüthje, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754987/ https://www.ncbi.nlm.nih.gov/pubmed/36522673 http://dx.doi.org/10.1186/s13256-022-03695-y

Ejemplares similares

Patient-specific factors affecting survival following hip fractures—a 14-year follow-up study in Finland
por: Tiihonen, Raine, et al.
Publicado: (2022)

Evaluation of minimal fracture liaison service resource: costs and survival in secondary fracture prevention—a prospective one-year study in South-Finland
por: Lüthje, P., et al.
Publicado: (2021)

Acute uveitis following zoledronic acid infusion
por: Rathnam, Krishna Kumar, et al.
Publicado: (2009)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Relatively low and moderate pre-fracture serum 25-hydroxyvitamin D levels associated with the highest survival in elderly hip fracture patients in Finland: a minimum 3-year follow-up
por: Nurmi-Lüthje, I., et al.
Publicado: (2021)

Correction to: Relatively low and moderate pre-fracture serum 25-hydroxyvitamin D levels associated with the highest survival in elderly hip fracture patients in Finland: a minimum 3-year follow-up
por: Nurmi-Lüthje, I., et al.
Publicado: (2021)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
por: Yassin, Mohamed A., et al.
Publicado: (2020)

Severe hypocalcaemia following denosumab and iron infusion
por: Cohen, Adrienne, et al.
Publicado: (2022)

Zoledronic acid infusion for prevention and treatment of osteoporosis
por: Sunyecz, John A
Publicado: (2010)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
por: Kadaru, Tarun, et al.
Publicado: (2021)

Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid
por: Silverman, S. L., et al.
Publicado: (2010)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia
por: Tripathy, Sujit Kumar, et al.
Publicado: (2020)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
por: Body, Jean-Jacques, et al.
Publicado: (2017)

Remarkable improvement in serum 25-hydroxyvitamin levels among hip fracture patients over a 12-year period: a prospective study in South-eastern Finland
por: Nurmi-Lüthje, I., et al.
Publicado: (2017)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Acute unilateral anterior uveitis following zoledronic acid infusion: A case report
por: Anandasayanan, Kiruththihan, et al.
Publicado: (2020)

THU449 An Unexpected Case Of Cutaneous Leukocytoclastic Vasculitis Following Zoledronic Acid Infusion
por: Zahedi, Bita, et al.
Publicado: (2023)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ
por: Roato, Ilaria, et al.
Publicado: (2023)

Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report
por: Panteliou, Eleftheria, et al.
Publicado: (2011)

A Rare Case of Acute Calcium Pyrophosphate Deposition Disease Following Zoledronic Acid Infusion
por: Florica, Roxana, et al.
Publicado: (2023)

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022)

Unmasking of Hypoparathyroidism by Zoledronic Acid Infusion in a Patient with Sheehan Syndrome
por: Viswanath, S Arun, et al.
Publicado: (2020)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Novel Strategies in the Prevention and Treatment of Urinary Tract Infections
por: Lüthje, Petra, et al.
Publicado: (2016)

Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis
por: Ferreira, Bruno S. A., et al.
Publicado: (2021)

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
por: Li, Shenglong, et al.
Publicado: (2019)

Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
por: Kondo, Hideomi, et al.
Publicado: (2020)

Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study
por: Nasser, Sahar M, et al.
Publicado: (2019)

Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
por: Kang, Taewook, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g4p85qhpr3v4e2p28prgq8hach